Erschienen in:
22.06.2017 | Editorial
Toward predictive biomarkers of response to kinase inhibitor therapies in differentiated thyroid cancer
verfasst von:
Nicole M. Iñiguez-Ariza, Keith C. Bible
Erschienen in:
Endocrine
|
Ausgabe 3/2017
Einloggen, um Zugang zu erhalten
Excerpt
Small-molecule kinase inhibitors have emerged as effective therapies for patients suffering from progressive, metastatic, radioiodine-refractory (RAIR) differentiated thyroid cancer (DTC) [
1]. Sorafenib and lenvatinib are now subject to regulatory approval in the United States and European Union for this indication [
2,
3], with other agents—including sunitinib, pazopanib, axitinib, vandetanib, and cabozantinib—also approved for other cancer indications and showing evidence of benefit in RAIR DTC based on phase 2 trial data [
1]. These kinase inhibitors are thought to demonstrate efficacy principally through their actions on vascular endothelial growth factors (VEGFRs), but they also inhibit many other kinases. Moreover, these systemically administered therapeutics are expected to inhibit targets not only in tumor, but also in host tissues, with potential therefore for their efficacies to be affected not only by tumor-specific, but also by host-specific, alterations [
1]. …